دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard
ArmandoStabileab†AntonyPellegrinoab†ElioMazzoneabDonatoCannolettaabMariode AngelisabFrancescoBarlettaabSimoneScuderiabVitoCucchiaraabGiorgioGandagliaabDanieleRaggicAndreaNecchicPierreKarakiewiczdFrancescoMontorsiabAlbertoBrigantiab
doi : 10.1016/j.euo.2021.08.001
Volume 5, Issue 1, February 2022, Pages 1-17
The role of positron emission tomography/computed tomography (PET/CT) with prostate-specific membrane antigen (PSMA) in the primary staging for patients with prostate cancer (PCa) is still debated.
Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel
Brandon A.Mahalab†TravisGerkec†ShivanshuAwasthicHoward R.SouledJonathan W.SimonsdAndreaMiyahiradSusanHalabieDanielGeorgefElizabeth A.PlatzghiLoreleiMuccijKosjYamoahc
doi : 10.1016/j.euo.2021.07.006
Volume 5, Issue 1, February 2022, Pages 18-29
Prostate cancer (PCa) is a complex disease that disproportionately impacts Black men in the USA. The structural factors that drive heterogeneous outcomes for patients of differing backgrounds are probably the same ones that result in population-level disparities. The relative contribution of drivers along the PCa disease continuum is an active area of investigation and debate.
Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors
ChiaraLonatiabAndreaNecchicdJuanGómez RivaseLucaAfferibEkaterinaLaukhtinafgAlbertoMartinihEugenioVentimigliahRenzoColombohGiorgioGandagliahAndreaSaloniachAlbertoBrigantichFrancescoMontorsichAgostinoMatteibClaudioSimeoneaMaria I.CarloiShahrokh F.ShariatfgjklPhilippe E.SpiessmMarcoMoschinibh
doi : 10.1016/j.euo.2021.11.001
Volume 5, Issue 1, February 2022, Pages 30-41
Upper tract urothelial carcinoma (UTUC) represents the third most frequent malignancy in Lynch syndrome (LS).
Upper Urinary Tract Urothelial Carcinoma in Lynch Syndrome Patients: The Urologist Still Has a Role in Genetic Screening
ElisabethGrobet-JeandinabUgoPinaraMorganRouprêta
doi : 10.1016/j.euo.2021.12.004
Volume 5, Issue 1, February 2022, Pages 42-43
Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography–staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial
TobiasHölscherabcdMichaelBaumannceJörgKotzerkebcdfKlausZöphelfgFrankPaulsenhArndt-ChristianMüllerhiDanielZipshcjLydiaKoiakChristianThomasbcdlSteffenLöckaecmMechthildKrauseabcdekmManfredWirthlFabianLohausabcdm
doi : 10.1016/j.euo.2021.10.002
Volume 5, Issue 1, February 2022, Pages 44-51
Local ablative radiotherapy (aRT) of oligometastatic prostate cancer (PCa) is very promising and has become a focus of current clinical research.
Metastases-directed Therapies in the Prostate-specific Membrane Antigen Era: Not All That Glitters Is Curable
doi : 10.1016/j.euo.2022.01.006
Volume 5, Issue 1, February 2022, Pages 52-53
Prostate Cancer Screening with Magnetic Resonance Imaging: Results from the Second Round of the Göteborg Prostate Cancer Screening 2 Trial
JonasWallströmabKjellGeterudbKimiaKohestanicdStephan E.MaierabCarl-GustafPihleAndreasSocratousbJohanStrannecdRebeckaArnsrud-GodtmancdMarianneMånssoncMikaelHellströmabJonasHugossoncd
doi : 10.1016/j.euo.2021.09.001
Volume 5, Issue 1, February 2022, Pages 54-60
The Göteborg 2 prostate cancer (PC) screening (G2) trial evaluates screening with prostate-specific antigen (PSA) followed by magnetic resonance imaging (MRI) in case of elevated PSA levels.
Characteristics of Cancer Progression on Serial Biopsy in Men on Active Surveillance for Early-stage Prostate Cancer: Implications for Focal Therapy
VittorioFasuloabcJanet E.CowanabMartinaMaggiabdSamuel L.WashingtonIIIabHao G.NguyenabKatsutoShinoharaabMassimoLazzericPaoloCasalecPeter R.Carrollab
doi : 10.1016/j.euo.2020.08.002
Volume 5, Issue 1, February 2022, Pages 61-69
Active surveillance (AS) is a safe and accepted option for managing men with low-risk prostate cancer. Nevertheless, some patients lack confidence in or access to AS. Focal therapy (FT) is a possible alternative to radical treatment for such patients.
Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non–muscle-invasive Bladder Cancer
Tessel E.GaleslootaAnne J.GrotenhuisaDimitarKolevaKatja K.AbenabRichard T.BryancdJames W.F.CattoeKar K.ChengfSamanthaConroyeLarsDyrskjøtghNeil E.FleshneriNicholas D.JamescPhilippeLamygSia ViborgLindskrogghNúriaMalatsjkLourdesMenguallGeraldVerhaeghmMaurice P.ZeegerscnoLambertus A.L.M.Kiemeneyam†Sita H.Vermeulenaâ€
doi : 10.1016/j.euo.2021.07.001
Volume 5, Issue 1, February 2022, Pages 70-83
Non–muscle-invasive bladder cancer (NMIBC) is characterized by frequent recurrences and a risk of progression in stage and grade. Increased knowledge of underlying biological mechanisms is needed.
Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin
NiyatiLoboaPatrick J.HensleyaKelly K.BreeaGraciela M.Nogueras-GonzalezbNeemaNavaiaColin P.DinneyaRichard J.SylvestercAshish M.Kamata
doi : 10.1016/j.euo.2021.11.006
Volume 5, Issue 1, February 2022, Pages 84-91
The 2021 European Association of Urology (EAU) guidelines contain updated prognostic factor risk groups for non–muscle-invasive bladder cancer (NMIBC). These groups are based on the following predictors of progression: tumour stage, grade, number, and size; concomitant carcinoma in situ; and age. However, the groups were derived from datasets excluding patients treated with bacillus Calmette-Guérin (BCG).
Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature
SrinivasNallandhighala†RandyVincea†RazeenKarimaSkylarGrovesabJudithStangl-KremseracChristopherRussellaKevinHudeTrinhPhamaAndi K.CanidfChia-JenLiudfAlexanderZaslavskyagRohitMehradfgMarcinCieslikdfTodd M.MorganagGanesh S.PalapattuacgAaron M.UdagerdfgSimpa S.Salamiadg
doi : 10.1016/j.euo.2021.10.007
Volume 5, Issue 1, February 2022, Pages 92-99
There is an ongoing need to develop prognostic biomarkers to improve the management of clear cell renal cell carcinoma (ccRCC).
Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging
Ting MartinMaaAndreiGafitabDavidShabsovichaJesusJuarezaTristan R.GrogancPanThinbWesleyArmstrongbIdaSonnibKathleenNguyenbVincentLokbRobert E.ReiterdMatthew B.RettigdeMichael L.SteinbergaPatrick A.KupelianaDavid D.YangfVinayakMuralidharfCarissaChugFelixFenggh…Amar U.Kishana
doi : 10.1016/j.euo.2021.01.006
Volume 5, Issue 1, February 2022, Pages 100-103
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is an emerging imaging modality with greater sensitivity and specificity over conventional imaging for prostate cancer (PCa) staging. Using data from two prospective trials (NCT03368547 and NCT04050215), we explored predictors of overall upstaging (nodal and metastatic) by PSMA PET/CT among patients with cN0M0 National Comprehensive Cancer Network high-risk PCa on conventional imaging (n = 213). Overall, 21.1%, 8.9%, and 23.9% of patients experienced nodal, metastatic, and overall upstaging, respectively, without histologic confirmation.
Three-dimensional Virtual Models’ Assistance During Minimally Invasive Partial Nephrectomy Minimizes the Impairment of Kidney Function
DanieleAmparorea†AngelaPecoraroa†EnricoCheccucciaFedericoPiramideaPaoloVerriaSabrinaDe CillisaStefanoGranatoaTizianaAngustibFedericaSolitrobAndreaVeltribCristianFioria‡FrancescoPorpigliaa‡
doi : 10.1016/j.euo.2021.04.001
Volume 5, Issue 1, February 2022, Pages 104-108
Three-dimensional virtual models (3DVMs) are nowadays under scrutiny to improve partial nephrectomy (PN) outcomes. This report aims to analyze their impact on renal function preservation after minimally invasive PN. A total of 100 patients treated with minimally invasive PN with contrast-enhanced computed tomography from which a 3DVM was obtained, and having undergone baseline and 3rd month postoperative renal scans were prospectively enrolled and compared with a control group of 251 patients without 3DVMs.
Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non–muscle-invasive Bladder Cancer
MateuszJobczykab†KonradStawiskic†MarcinKaszkowiakcPawełRajwadeWaldemarRóżańskiaFrancescoSoriaefShahrokh F.ShariateghijkWojciechFendlercl
doi : 10.1016/j.euo.2021.05.006
Volume 5, Issue 1, February 2022, Pages 109-112
Despite being standard tools for decision-making, the European Organisation for Research and Treatment of Cancer (EORTC), European Association of Urology (EAU), and Club Urologico Espanol de Tratamiento Oncologico (CUETO) risk groups provide moderate performance in predicting recurrence-free survival (RFS) and progression-free survival (PFS) in non–muscle-invasive bladder cancer (NMIBC). In this retrospective combined-cohort data-mining study, the training group consisted of 3570 patients with de novo diagnosed NMIBC.
Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma
Michael A.Gorinabc†Hiten D.Patela†Steven P.RoweabNoah M.HahnacHans J.HammersdAlicePonsceBruce J.TrockaPhillip M.PierorazioacThomas R.NirschlceDaniela C.SallesfJulie E.SteinfTamara L.LotanfJanis M.TaubeefCharles G.DrakegMohamad E.Allafac
doi : 10.1016/j.euo.2021.04.002
Volume 5, Issue 1, February 2022, Pages 113-117
Neoadjuvant immune checkpoint blockade represents a novel approach for potentially decreasing the risk of recurrence in patients with nonmetastatic renal cell carcinoma (RCC). In this early phase clincal tiral, we evaluated the safety and tolerability of neoadjuvant treatment with the programmed cell death protein 1 (PD-1) inhibitor nivolumab in patients with nonmetastatic high-risk RCC.
Locally Advanced Kidney Cancer: A New Space for Immunotherapy?
NirmishSinglaaVitalyMargulisbc
doi : 10.1016/j.euo.2021.05.003
Volume 5, Issue 1, February 2022, Pages 118-119
Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy
EkaterinaLaukhtinaabFahadQuhalacKeiichiroMoriadRezaSari MotlaghaePawelRajwaafTakafumiYanagisawaadHadiMostafaeiagFrederikKönigahAbdulmajeedAydhaiBenjaminPradereaDmitryEnikeevbPierre I.KarakiewiczjManuelaSchmidingeraShahrokh F.Shariatabklmno
doi : 10.1016/j.euo.2021.12.007
Volume 5, Issue 1, February 2022, Pages 120-124
We determined the oncologic outcomes and safety profiles of adjuvant immune checkpoint inhibitors (ICIs) compared to adjuvant tyrosine kinase inhibitors (TKIs) in patients at high risk after nephrectomy for clinically nonmetastatic renal cell carcinoma (RCC). Network meta-analyses were conducted for disease-free survival (DFS), overall survival (OS), and adverse events (AEs) with placebo as the common comparator arm.
Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma: Current Recommendations and Future Insights
DanielBenamranaLaurenceAlbigesbAxelBexcGianlucaGiannarinidUmbertoCapitanioeMorganRouprêtfon behalf of the EAU Section of Oncological Urology (ESOU) Board
doi : 10.1016/j.euo.2021.08.003
Volume 5, Issue 1, February 2022, Pages 125-133
This clinical case–based discussion focuses on a 73-yr-old man diagnosed with intermediate-risk oligometastatic clear-cell renal cell carcinoma (RCC) and treated with systemic therapy. Current guideline-based treatment options are presented and critically examined.
